Quanterix (QTRX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 May, 2026Executive summary
The annual meeting is scheduled for June 9, 2026, and will be held virtually for shareholder participation.
The proxy supplement updates Proposal No. 4 regarding amendments to the 2017 Equity Incentive Plan, reinstating and adding award limitations.
All other information in the original proxy statement remains unchanged except as updated by this supplement.
Voting matters and shareholder proposals
Shareholders will vote on the election of directors, executive compensation (say-on-pay), ratification of KPMG LLP as auditor, and approval of the amended 2017 Equity Incentive Plan.
Proposal No. 4 amends the 2017 Plan to reinstate a per-participant annual share award limit and adds a cap on non-employee director compensation.
Proxy cards already submitted remain valid; no new cards are required due to the supplement.
Board of directors and corporate governance
The Board recommends voting FOR all director nominees and FOR all proposals.
The Board delegated authority to officers and the Compensation Committee Chair to approve amendments to the equity plan.
Latest events from Quanterix
- Q1 2026 revenue up 20% to $36.4M, with improved margins and $85M in cost synergies.QTRX
Q1 20266 May 2026 - Diagnostics and diversification drive growth as financial discipline and innovation strengthen outlook.QTRX
Leerink Global Healthcare Conference 202629 Apr 2026 - Annual meeting to vote on directors, executive pay, auditor, and equity plan amendment.QTRX
Proxy filing24 Apr 2026 - Diagnostics and recurring revenue drive growth, with Alzheimer's and Akoya integration as key priorities.QTRX
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Q4 revenue up 25% year-over-year; 2026 targets include breakeven and strong growth.QTRX
Q4 20252 Mar 2026 - Sustained growth, new platforms, and Akoya integration drive expansion and profitability.QTRX
43rd Annual J.P. Morgan Healthcare Conference 20253 Feb 2026 - Blood-based diagnostics and multi-marker innovation drive growth, margin gains, and future strategy.QTRX
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Q2 revenue up 11% to $34.4M, net loss widened, 2024 outlook lowered amid capital constraints.QTRX
Q2 20242 Feb 2026 - Strong service growth and multiplex assay innovation drive expansion in neurology diagnostics.QTRX
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026